Testing a new bladder cancer treatment using targeted drug delivery

Plain-English translation of NCT05519241 on ClinicalTrials.gov ↗ · Source last updated September 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new treatment called paclitaxel-loaded micelles (PPM) designed specifically to target bladder cancer cells. The medication is delivered directly into the bladder through a catheter rather than given as a pill or injection into the bloodstream. This is the first time this treatment is being tested in humans with non-muscle-invasive bladder cancer.

Many patients with bladder cancer stop responding to the standard first-line treatment (BCG therapy), and need new options before considering surgery to remove the bladder. This medication aims to deliver chemotherapy directly to cancer cells while minimizing side effects to the rest of the body.

Do you qualify?

You likely qualify if…

you have been diagnosed with non-muscle-invasive bladder cancer that did not respond to BCG treatment or you could not tolerate BCG
your cancer was confirmed by biopsy within the last 3 months and there is no evidence it has invaded the deeper muscle layer of the bladder
you are at least 18 years old with a life expectancy of more than 2 years
you have acceptable kidney, liver, and bone marrow function as shown by recent blood tests
you are in generally good health (ECOG performance status of 0, 1, or 2)

You likely don't qualify if…

you are currently receiving or planning to receive chemotherapy, radiation, immunotherapy, or other cancer surgery before the study is complete
you have severe lung disease or other conditions that would make treatment unsafe
you are pregnant or nursing, or unwilling to use birth control during the trial
you have severely abnormal kidney function (GFR less than 50 mL/min)

What participation looks like

You would receive weekly infusions of the medication directly into your bladder for 6 weeks. Each infusion is given through a catheter (a thin tube inserted into the bladder). After treatment ends, you will have follow-up visits with imaging and urine tests to check whether the cancer has responded. The trial will monitor you closely for side effects throughout the 6-week treatment period and beyond.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(1 site)

United States

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts